Targeting Nur77 translocation

Expert Opinion on Therapeutic Targets

Volumn 11, Issue 1, 2007, Pages 69-79

  Zhang, Xiao Kun ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b XIAMEN UNIVERSITY   (China)

Author keywords

AHPN; Apoptosis; Bcl 2; CD437; Mitochondria; Nur77; Retinoid X receptor; TR3

Indexed keywords

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ANTINEOPLASTIC AGENT; APOPTIN; BUTYRIC ACID; CADMIUM; CHENODEOXYCHOLIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOCHROME C; DIBUTYLTIN DICHLORIDE; DNA; DOCOSAHEXAENOIC ACID; DOXORUBICIN; ENZYME INHIBITOR; ETODOLAC; ETOPOSIDE; FATTY ACID DERIVATIVE; FLUOROURACIL; HISTONE ACETYLTRANSFERASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; HYPERICUM SAMSONII EXTRACT; IMATINIB; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEAR RECEPTOR NUR77; PACLITAXEL; PROTEIN BCL 2; RETINOIC ACID; RETINOID X RECEPTOR; SULINDAC; TOLUENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL; CANCER CELL DESTRUCTION; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL PROTECTION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONFORMATIONAL TRANSITION; DEGENERATIVE DISEASE; DNA BINDING; DNA DAMAGE; DRUG RECEPTOR BINDING; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE TRANSLOCATION; HELA CELL; HERB; HUMAN; HYPERICUM SAMSONII; LUNG CANCER; LUNG NON SMALL CELL CANCER; MITOCHONDRION; MITOSIS INHIBITION; MOUTH CARCINOMA; NONHUMAN; OVARY CANCER; PATHOPHYSIOLOGY; PROGNOSIS; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; TRANSCRIPTION REGULATION;

ANIMALS; APOPTOSIS; CELL NUCLEUS; CELL SURVIVAL; DNA-BINDING PROTEINS; HUMANS; MITOCHONDRIA; NEOPLASMS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, STEROID; RETINOID X RECEPTORS; RETINOIDS; TRANSCRIPTION FACTORS;

EID: 33846221824     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.11.1.69     Document Type: Review

References (132)

1. HANAHAN D, WEINBERG RA: The hallmarks of cancer. Cell (2000) 100(1):57-70.
2. GREEN DR, KROEMER G: The pathophysiology of mitochondrial cell death. Science (2004) 305(5684):626-629.
3. REED JC: Apoptosis-based therapies. Nat. Rev. Drug Discov. (2002) 1(2):111-121.
4. CHANG C, KOKONTIS J, LIAO SS, CHANG Y: Isolation and characterization of human TR3 receptor: a member of steroid receptor superfamily. J. Steroid Biochem. (1989) 34(1-6):391-395.
5. LIM RW, VARNUM BC, HERSCHMAN HR: Cloning of tetradecanoyl phorbol ester-induced 'primary response' sequences and their expression in density-arrested Swiss 3T3 cells and a TPA non-proliferative variant. Oncogene (1987) 1(3):263-270.
6. HAZEL TG, NATHANS D, LAU LF: A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. Proc. Natl. Acad. Sci. USA (1988) 85(22):8444-8448.
7. MILBRANDT J: Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene. Neuron (1988) 1(3):183-188.
8. ZHANG XK: Vitamin A and apoptosis in prostate cancer. Endocr. Relat. Cancer (2002) 9(2):87-102.
9. MARTINEZ-GONZALEZ J, BADIMON L: The NR4A subfamily of nuclear receptors: new early genes regulated by growth factors in vascular cells. Cardiovasc. Res. (2005) 65(3):609-618.
10. HSU HC, ZHOU T, MOUNTZ JD: Nur77 family of nuclear hormone receptors. Curr. Drug Targets Inflamm. Allergy (2004) 3(4):413-423.
11. FERRI KF, KROEMER G: Mitochondria-the suicide organelles. Bioessays (2001) 23(2):111-115.
12. LI QX, KE N, SUNDARAM R, WONG-STAAL F: NR4A1, 2, 3-an orphan nuclear hormone receptor family involved in cell apoptosis and carcinogenesis. Histol. Histopathol. (2006) 21(5):533-540.
13. MAXWELL MA, MUSCAT GE: The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. Nucl. Recept. Signal (2006) 4:e002.
14. MANGELSDORF DJ, EVANS RM: The RXR heterodimers and orphan receptors. Cell (1995) 83(6):841-850.
15. KASTNER P, MARK M, CHAMBON P: Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? Cell (1995) 83(6):859-869.
16. WU Q, LIU S, YE XF, HUANG ZW, SU WJ: Dual roles of Nur77 in selective regulation of apoptosis and cell cycle by TPA and ATRA in gastric cancer cells. Carcinogenesis (2002) 23(10):1583-1592.
17. WU WS, XU ZX, RAN R, MENG F, CHANG KS: Promyelocytic leukemia protein PML inhibits Nur77-mediated transcription through specific functional interactions. Oncogene (2002) 21(24):3925-3933.
18. JEONG JH, PARK JS, MOON B et al.: Orphan nuclear receptor Nur77 translocates to mitochondria in the early phase of apoptosis induced by synthetic chenodeoxycholic acid derivatives in human stomach cancer cell line SNU-1. Ann. NY Acad. Sci. (2003) 1010:171-177.
19. UEMURA H, CHANG C: Antisense TR3 orphan receptor can increase prostate cancer cell viability with etoposide treatment. Endocrinology (1998) 139(5):2329-2334.
20. HOLLA VR, MANN JR, SHI Q, DUBOIS RN: Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J. Biol. Chem. (2006) 281(5):2676-2682.
21. MADDIKA S, BOOY EP, JOHAR D et al.: Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77-dependent pathway. J. Cell Sci. (2005) 118(Pt 19):4485-4493.
22. KOLLURI SK, CAO X, BRUEY-SEDANO N et al.: Mitogenic effect of orphan receptor TR3 and its regulation by MEKK1 in lung cancer cells. Mol. Cell. Biol. (2003) 23:8651-8667.
23. KE N, CLAASSEN G, YU DH et al.: Nuclear hormone receptor NR4A2 is involved in cell transformation and apoptosis. Cancer Res. (2004) 64(22):8208-8212.
24. LEE MO, KANG HJ, CHO H et al.: Hepatitis B virus X protein induced expression of the Nur77 gene. Biochem. Biophys. Res. Commun. (2001) 288(5):1162-1168.
25. LABELLE Y, ZUCMAN J, STENMAN G et al.: Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Hum. Mol. Genet. (1995) 4(12):2219-2226.
26. LABELLE Y, BUSSIERES J, COURJAL F, GOLDRING MB: The EWS/TEC fusion protein encoded by the t(9;22) chromosomal translocation in human chondrosarcomas is a highly potent transcriptional activator. Oncogene (1999) 18(21):3303-3308.
27. CHEN GQ LIN B, DAWSON MI, ZHANG XK: Nicotine modulates the effects of retinoids on growth inhibition and RAR β expression in lung cancer cells. Int. J. Cancer (2002) 99(2):171-178.
28. WU Q, LI Y, LIU R et al.: Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization. EMBO J. (1997) 16(7):1656-1669.
29. WU Q, DAWSON MI, ZHENG Y et al.: Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids. Mol. Cell. Biol. (1997) 17(11):6598-6608.
30. YOO YG, YEO MG, KIM DK, PARK H, LEE MO: Novel function of orphan nuclear receptor Nur77 in stabilizing hypoxia-inducible factor-1α. J. Biol. Chem. (2004) 279(51):53365-53373.
31. LIU D, JIA H, HOLMES DI, STANNARD A, ZACHARY I: Vascular endothelial growth factor-regulated gene expression in endothelial cells: KDR-mediated induction of Egr3 and the related nuclear receptors Nur77, Nurr1, and Nor1. Arterioscler. Thromb. Vasc. Biol. (2003) 23(11):2002-2007.
32. PEI L, CASTRILLO A, CHEN M, HOFFMANN A, TONTONOZ P: Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli. J. Biol. Chem. (2005) 280(32):29256-29262.
33. PEI L, CASTRILLO A, TONTONOZ P: Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77. Mol. Endocrinol. (2006) 20(4):786-794.
34. DE LESELEUC L, DENIS F: Inhibition of apoptosis by Nur77 through NF-kappaB activity modulation. Cell Death Differ. (2006) 13(2):293-300.
35. BRAS A, ALBAR JP, LEONARDO E, DE BUITRAGO GG, MARTINEZ AC: Ceramide-induced cell death is independent of the Fas/Fas ligand pathway and is prevented by Nur77 overexpression in A20 B cells. Cell Death Differ. (2000) 7(3):262-271.
36. SUZUKI S, SUZUKI N, MIRTSOS C et al.: Nur77 as a survival factor in tumor necrosis factor signaling. Proc. Natl. Acad. Sci. USA (2003) 100(14):8276-8280.
37. LIU ZG, SMITH SW, MCLAUGHLIN KA, SCHWARTZ LM, OSBORNE BA: Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77. Nature (1994) 367(6460):281-284.
38. WORONICZ JD, CALNAN B, NGO V, WINOTO A: Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas. Nature (1994) 367(6460):277-281.
39. LI Y, LIN B, AGADIR A et al.: Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol. Cell. Biol. (1998) 18(8):4719-4731.
40. HOLMES WF, SOPRANO DR, SOPRANO KJ: Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines. J. Cell. Physiol. (2004) 199(3):317-329.
41. PFAHL M, PIEDRAFITA FJ: Retinoid targets for apoprosis induction. Oncogene (2003) 22(56):9058-9062.
42. LOTAN R: Receptor-independent induction of apoptosis by synthetic retinoids. J. Biol. Regul. Homeost. Agents (2003) 17(1):13-28.
43. FONTANA JA, RISHI AK: Classical and novel retinoids: their targets in cancer therapy. Leukemia (2002) 16(4):463-472.
44. COSTANTINI P, JACOTOT E, DECAUDIN D, KROEMER G: Mitochondrion as a novel target of anticancer chemotherapy. J. Natl. Cancer Inst. (2000) 92(13):1042-1053.
45. HOLMES WF, SOPRANO DR, SOPRANO KJ: Early events in the induction of apoptosis in ovarian carcinoma cells by CD437: activation of the p38 MAP kinase signal pathway. Oncogene (2003) 22(41):6377-6386.
46. LI H, KOLLURI SK, GU J et al.: Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3 [see comments] [comment]. Science (2000) 289(5482):1159-1164.
47. LIU S: Induction of apoptosis by TPA and VP-16 is through translocation of TR3. World J. Gastroenterol. (2002) 8(3):446-450.
48. CAO X, LIU W, LIN F et al.: Retinoid X receptor regulates Nur77/ TR3-dependent apoptosis by modulating its nuclear export and mitochondrial targeting. Mol. Cell. Biol. (2004) 24(22):9705-9725.
49. LIN B, KOLLURI S, LIN F et al.: Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell (2004) 116:527-540.
50. GENNARI A, BLEUMINK R, VTVIANI B et al.: Identification by DNA macroarray of nur77 as a gene induced by di-n-butyltin dichloride: its role in organotin-induced apoptosis. Toxicol Appl. Pharmacol. (2002) 181(1):27-31.
51. CHINNAIYAN P, VARAMBALLY S, TOMLINS SA et al.: Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int. J. Cancer (2006) 118(4):1041-1050.
52. SHIN HJ, LEE BH, YEO MG et al.: Induction of orphan nuclear receptor Nur77 gene expression and its role in cadmium-induced apoptosis in lung. Carcinogenesis (2004) 25(8):1467-1475.
53. CHINTHARLAPALLI S, BURGHARDT R, PAPINENI S et al.: Activation of Nur77 by selected 1, 1-Bis(3′-indolyl)-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways. J. Biol. Chem. (2005) 280(26):24903-24914.
54. SHIPP MA, ROSS KN, TAMAYO P et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. (2002) 8(1):68-74.
55. RAMASWAMY S, ROSS KN, LANDER ES, GOLUB TR: A molecular signature of metastasis in primary solid tumors. Nat. Genet. (2003) 33(1):49-54.
56. WORONICZ JD, LINA A, CALNAN BJ et al.: Regulation of the Nur77 orphan steroid receptor in activation-induced apoptosis. Mol. Cell. Biol. (1995) 15(11):6364-6376.
57. HAZEL TG, MISRA R, DAVIS IJ, GREENBERG ME, LAU LF: Nur77 is differentially modified in PC12 cells upon membrane depolarization and growth factor treatment. Mol. Cell. Biol. (1991) 11(6):3239-3246.
58. DAVIS IJ, HAZEL TG, CHEN RH, BLENIS J, LAU LF: Functional domains and phosphorylation of the orphan receptor Nur77. Mol. Endocrinol. (1993) 7(8):953-964.
59. FAHRNER TJ, CARROLL SL, MILBRANDT J: The NGFI-B protein, an inducible member of the thyroid/steroid receptor family, is rapidly modified posttranslationally. Mol. Cell. Biol. (1990) 10(12):6454-6459.
60. KATAGIRI Y, TAKEDA K, YU ZX et al.: Modulation of retinoid signalling through NGF-induced nuclear export of NGFI-B. Nat. Cell. Biol. (2000) 2(7):435-440.
61. HOLMES WF, SOPRANO DR, SOPRANO KJ: Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR. J. Cell. Biochem. (2003) 89(2):262-278.
62. DAWSON MI, HOBBS PD, PETERSON VJ et al.: Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-na phthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res. (2001) 61(12):4723-4730.
63. LEE KW, MA L, YAN X et al.: Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRα/Nur77. J. Biol. Chem. (2005) 280(17):16942-16948.
64. WILSON AJ, ARANGO D, MARIADASON JM, HEERDT BG, AUGENLICHT LH: TR3/Nur77 in colon cancer cell apoptosis. Cancer Res. (2003) 63(17):5401-5407.
65. LEE JM, LEE KH, WEIDNER M, OSBORNE BA, HAYWARD SD: Epstein-Barr virus EBNA2 blocks Nur77-mediated apoptosis. Proc. Natl. Acad. Sci. USA (2002) 99(18):11878-11883.
66. LEE JM, LEE KH, FARRELL CJ et al.: EBNA2 is required for protection of latently Epstein-Barr virus-infected B cells against specific apoptotic stimuli. J. Virol. (2004) 78(22):12694-12697.
67. JACOBS CM, BOLDINGH KA, SLAGSVOLD HH, THORESEN GH, PAULSEN RE: ERK2 prohibits apoptosis-induced subcellular translocation of orphan nuclear receptor NGFI-B/TR3. J. Biol. Chem. (2004) 279(48):50097-50101.
68. CHENG EH, KIRSCH DG, CLEM RJ et al.: Conversion of Bcl-2 to a Bax-like death effector by caspases. Science (1997) 278(5345):1966-1968.
69. GRANDGIRARD D, STUDER E, MONNEY L et al.: Alphaviruses induce apoptosis in Bcl-2-overexpressing cells: evidence for a caspase-mediated, proteolytic inactivation of Bcl-2. EMBO J. (1998) 17(5):1268-1278,
70. SUBRAMANIAN T, CHINNADURAI G: Pro-apoprotic activity of transiently expressed BCL-2 occurs independent of BAX and BAK. J. Cell. Biochem. (2003) 89(6):1102-1114.
71. UHLMANN EJ, SUBRAMANIAN T, VATER CA, LUTZ R, CHINNADURAI G: A potent cell death activity associated with transient high level expression of BCL-2. J. Biol. Chem. (1998) 273(28):17926-17932.
72. XUE D, HORVITZ HR: Caenorhabditis elegans CED-9 protein is a bifunctional cell-death inhibitor. Nature (1997) 390(6657):305-308.
73. IGAKI T, KANUKA H, INOHARA N et al.: Drob-1, a Drosophila member of the Bcl-2/CED-9 family that promotes cell death. Proc. Natl. Acad. Sci. USA (2000) 97(2):662-667.
74. DAIDONE MG, LUISI A, VENERONI S, BENINI E, SILVESTRINI R: Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr. Relat. Cancer (1999) 6(1):61-68.
75. GASPARINI G, BARBARESCHI M, DOGLIONI C et al.: Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer. Clin. Cancer Res. (1995) 1(2):189-198.
76. CATZ SD, JOHNSON JL: BCL-2 in prostate cancer: a minireview. Apoptosis (2003) 8(1):29-37.
77. MARTIN B, PAESMANS M, BERGHMANS T et al.: Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br. J. Cancer (2003) 89(1):55-64.
78. KROGER N, MILDE-LANGOSCH K, RIETHDORF S et al.: Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin. Cancer Res. (2006) 12(1):159-168.
79. WATSON NF, MADJD Z, SCRIMEGOUR D et al.: Evidence that the p53 negative/ Bcl-2 positive phenotype is an independent indicator of good prognosis in colorectal cancer: a tissue microarray study of 460 patients. World J. Surg. Oncol. (2005) 3:47.
80. OFNER D, RIEHEMANN K, MAIER H et al.: Immunohistochemically detectable bcl-2 expression in colorectal carcinoma: correlation with tumour stage and patient survival. Br. J. Cancer (1995) 72(4):981-985.
81. SINICROPE FA, HART J, MICHELASSI F, LEE JJ: Prognostic value of bcl-2 oncoprorein expression in stage II colon carcinoma. Clin. Cancer Res. (1995) 1(10):1103-1110.
82. KONDO E, MIYAKE T, SHIBATA M et al.: Expression of phosphorylated Ser70 of Bcl-2 correlates with malignancy in human colorectal neoplasms. Clin. Cancer Res. (2005) 11(20):7255-7263.
83. LO MUZIO L, FALASCHINI S, FARINA A et al.: Bcl-2 as prognostic factor in head and neck squamous cell carcinoma. Oncol. Res. (2005) 15(5):249-255.
84. STEINERT DM, OYARZO M, WANG X et al.: Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer (2006) 106(7):1617-1623.
85. CORY S, HUANG DC, ADAMS JM: The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene (2003) 22(53):8590-8607.
86. REED JC: Bcl-2 family proteins. Oncogene (1998) 17(25):3225-3236.
87. SRIVASTAVA RK, MI QS, HARDWICK JM, LONGO DL: Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc. Natl. Acad. Sci. USA (1999) 96(7):3775-3780.
88. HALDAR S, JENA N, CROCE CM: Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA (1995) 92(10):4507-4511.
89. YAMAMOTO K, ICHIJO H, KORSMEYER SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol. Cell. Biol. (1999) 19(12):8469-8478.
90. DEVERMAN BE, COOK BL, MANSON SR et al.: Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage. Cell (2002) 111(1):51-62.
91. WEI MC, ZONG WX, CHENG EH et al.: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science (2001) 292(5517):727-730.
92. WEI MC, LINDSTEN T, MOOTHA VK et al.: tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev. (2000) 14(16):2060-2071.
93. ORIDATE N, HIGUCHI M, SUZUKI S et al.: Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)hydroxyphenyl]-2-napht alene carboxylic acid (CD437). Int. J. Cancer (1997) 70(4):484-487.
94. LANGDON SP, RABIASZ GJ, RITCHIE AA et al.: Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo. Cancer Chemother. Pharmacol. (1998) 42(5):429-432.
95. LIANG JY, FONTANA JA, RAO JN et al.: Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3. Prostate (1999) 38(3):228-236.
96. SCHADENDORF D, KERN MA, ARTUC M et al.: Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J. Cell. Biol. (1996) 135(6 Pt 2):1889-1898.
97. GIANNI M, DE THE H: In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARα protein and the PML retargeting on PML-nuclear bodies. Leukemia (1999) 13(5):739-749.
98. HSU CA, RISHI AK, SU-LI X et al.: Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor-independent pathway. Blood (1997) 89(12):4470-4479.
99. ADACHI H, PRESTON G, HARVAT B, DAWSON MI, JETTEN AM: Inhibition of cell proliferation and induction of apoptosis by the retinoid AHPN in human lung carcinoma cells. Am. J. Respir. Cell Mol. Biol. (1998) 18(3):323-333.
100. 3 and a novel apoptosis-inducing retinoid on breast cancer and endothelial cell growth. Cancer Lett. (1998) 133(1):1-8.
101. WIDSCHWENDTER M, DAXENBICHLER G, CULIG Z et al.: Activity of retinoic acid receptor-gamma selectively binding retinoids alone and in combination with interferon-gamma in breast cancer cell lines. Int. J. Cancer (1997) 71(3):497-504.
102. SHAO ZM, DAWSON MI, LI XS et al.: p53 independent G0/G1 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene (1995) 11(3):493-504.
103. HAN YH, CAO, X, LIN B et al.: Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt. Oncogene (2006) 25(21):2974-2986.
104. JACOBS CM, PAULSEN RE: Crosstalk between ERK2 and RXR regulates nuclear import of transcription factor NGFI-B. Biochem. Biophys. Res. Commun. (2005) 336(2):646-652.
105. SLAGSVOLD HH, OSTVOLD AC, FALLGREN AB, PAULSEN RE: Nuclear receptor and apoptosis initiator NGFI-B is a substrate for kinase ERK2. Biochem. Biophys. Res. Commun. (2002) 291(5):1146-1150.
106. MASUYAMA N, OISHI K, MORI Y et al.: Akt inhibits the orphan nuclear receptor Nur77 and T-cell apoptosis. J. Biol. Chem. (2001) 276(35):32799-32805.
107. PEKARSKY Y, HALLAS C, PALAMARCHUK A et al.: Akt phosphorylates and regulates the orphan nuclear receptor Nur77. Proc. Natl. Acad. Sci. USA (2001) 98(7):3690-3694.
108. SWANSON KD, TAYLOR LK, HAUNG L, BURLINGAME AL, LANDRETH GE: Transcription factor phosphorylation by pp90(rsk2). Identification of Fos kinase and NGFI-B kinase I as pp90(rsk2). J. Biol. Chem. (1999) 274(6):3385-3395.
109. WINGATE AD, CAMPBELL DG, PEGGIE M, ARTHUR JS: Nur77 is phosphorylated in cells by RSK in response to mitogenic stimulation. Biochem. J (2005) 393:715-724.
110. CHEN RH, BLENIS J: Identification of Xenopus S6 protein kinase homologs (pp90rsk) in somatic cells: phosphorylation and activation during initiation of cell proliferation. Mol. Cell. Biol. (1990) 10(6):3204-3215.
111. CHEN RH, CHUNG J, BLENIS J: Regulation of pp90rsk phosphorylation and S6 phosphotransferase activity in Swiss 3T3 cells by growth factor-, phorbol ester-, and cyclic AMP-mediated signal transduction. Mol. Cell. Biol. (1991) 11(4):1861-1867.
112. LIN XF, ZHAO BX, CHEN HZ et al.: RXRα acts as a carrier for TR3 nuclear export in a 9-cis retinoic acid-dependent manner in gastric cancer cells. J. Cell Sci. (2004) 117(Pt 23):5609-5621.
113. BISSONNETTE RP, BRUNNER T, LAZARCHIK SB et al.:9-cis retinoic acid inhibition of activation-induced apoptosis is mediated via regulation of fas ligand and requires retinoic acid receptor and retinoid X receptor activation. Mol. Cell. Biol. (1995) 15(10):5576-5585.
114. YANG Y, VACCHIO MS, ASHWELL JD: 9-cis-retinoic acid inhibits activation-driven T-cell apoptosis: implications for retinoid X receptor involvement in thymocyte development. Proc. Natl. Acad. Sci. USA (1993) 90(13):6170-6174.
115. YANG Y, BAILEY J, VACCHIO MS, YARCHOAN R, ASHWELL JD: Retinoic acid inhibition of ex vivo human immunodeficiency virus-associated apoptosis of peripheral blood cells. Proc. Natl. Acad. Sci. USA (1995) 92(7):3051-3055.
116. MEINKE G, SIGLER PB: DNA-binding mechanism of the monomeric orphan nuclear receptor NGFI-B. Nat. Struct. Biol. (1999) 6(5):471-477.
117. KOLLURI SK, CORR M, JAMES SY et al.: The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Proc. Natl. Acad. Sci. USA (2005) 102(7):2525-2530.
118. DE URQUIZA AM, LIU S, SJOBERG M et al.: Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science (2000) 290(5499):2140-2144.
119. LEE SL, WESSELSCHMIDT RL, LINETTE GP et al.: Unimpaired thymic and peripheral T cell death in mice lacking the nuclear receptor NGFI-B (Nur77). Science (1995) 269(5223):532-535.
120. CHENG LE, CHAN FK, CADO D, WINOTO A: Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis. EMBO J. (1997) 16(8):1865-1875.
121. CALNAN BJ, SZYCHOWSKI S, CHAN FK, CADO D, WINOTO A: A role for the orphan steroid receptor Nur77 in apoptosis accompanying antigen-induced negative selection. Immunity (1995) 3(3):273-282.
122. ZHOU T, CHENG J, YANG P et al.: Inhibition of Nur77/Nurr1 leads to inefficient clonal deletion of self-reactive T cells. J. Exp. Med. (1996) 183(4):1879-1892.
123. SUN SY, YUE P, CHEN X, HONG WK, LOTAN R: The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells. Cancer Res. (2002) 62(8):2430-2436.
124. MADDIKA S, MENDOZA FJ, HAUFF K et al.: Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol. Ther. (2006) 5(1):10-19.
125. DAWSON MI, FONTANA JA, ZHANG X-K, LEID M, JONG L, HOBBS PD: Induction of apoptosis in cancer cells. The Burnham Institute, USA (2006).
126. BOURGUET W, VIVAT V, WURTZ JM et al.: Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell (2000) 5(2):289-298.
127. EGEA PF, MITSCHLER A, ROCHEL N et al.: Crystal structure of the human RXRα ligand-binding domain bound to its natural ligand:9-cis retinoic acid. EMBO J. (2000) 19(11):2592-2601.
128. ZENG JZ, SUN DF, WANG L et al.: Hypericum sampsonii induces apoptosis and nuclear export of retinoid X receptor-alpha. Carcinogenesis (2006). (In Press).
129. BAKER KD, SHEWCHUK LM, KOZLOVA T et al.: The Drosophila orphan nuclear receptor DHR38 mediates an atypical ecdysteroid signaling pathway. Cell (2003) 113(6):731-742.
130. WANG Z, BENOIT G, LIU J et al.: Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors. Nature (2003) 423(6939):555-560.
131. KAGAYA S, OHKURA N, TSUKADA T et al.: Prostaglandin A2 acts as a transactivator for NOR1 (NR4A3) within the nuclear receptor superfamily. Biol. Pharm. Bull. (2005) 28(9):1603-1607.
132. REED JC, ZHANG X-K, BING G, LIN B, KOLLURI SK: Conversion of apoptotic proteins. The Burnham Institute, USA (2006).